On Nov 09, major Wall Street analysts update their ratings for $Moderna (MRNA.US)$, with price targets ranging from $60 to $112.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $70.
Goldman Sachs analyst Salveen Richter maintains with a buy rating, and adjusts the target price from $139 to $112.
BofA Securities analyst Alec Stranahan maintains with a hold rating, and adjusts the target price from $110 to $90.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $125 to $111.
Evercore analyst Cory Kasimov maintains with a hold rating, and maintains the target price at $60.
Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:
Moderna's Q3 SpikeVax revenue exceeded expectations and the company maintained its previous guidance. Despite anticipating the approval of two additional vaccines, the company presented a prudent projection for the year 2025.
Moderna's recent quarterly performance surpassed expectations, mainly due to an earlier commencement of the vaccination season compared to the previous year. Nonetheless, the company has moderated its vaccination rate outlook for the year, shifting from 'flat' in comparison to last year to a potential decline of up to 10%. Additionally, while revenue guidance for the year remains unchanged, expectations have been adjusted to conclude towards the lower end of the projected range.
Here are the latest investment ratings and price targets for $Moderna (MRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月9日，多家華爾街大行更新了$Moderna (MRNA.US)$的評級，目標價介於60美元至112美元。
摩根士丹利分析師Terence Flynn維持持有評級，維持目標價70美元。
高盛集團分析師Salveen Richter維持買入評級，並將目標價從139美元下調至112美元。
美銀證券分析師Alec Stranahan維持持有評級，並將目標價從110美元下調至90美元。
巴克萊銀行分析師Gena Wang維持買入評級，並將目標價從125美元下調至111美元。
Evercore分析師Cory Kasimov維持持有評級，維持目標價60美元。
此外，綜合報道，$Moderna (MRNA.US)$近期主要分析師觀點如下：
以下爲今日6位分析師對$Moderna (MRNA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
